Collegium Pharmaceutical Inc. (NASDAQ:COLL) shares fell 4.7% during mid-day trading on Wednesday . The stock traded as low as $10.78 and last traded at $10.87, with a volume of 102,049 shares. The stock had previously closed at $11.41.

Several brokerages have recently issued reports on COLL. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a report on Monday, August 15th. Piper Jaffray Cos. restated a “buy” rating and issued a $27.00 price objective (up from $26.00) on shares of Collegium Pharmaceutical in a report on Thursday, June 23rd. Finally, Needham & Company LLC restated a “buy” rating and issued a $30.00 price objective (up from $28.00) on shares of Collegium Pharmaceutical in a report on Thursday, May 26th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $28.25.

The firm’s 50 day moving average price is $11.92 and its 200-day moving average price is $15.68. The company’s market capitalization is $247.75 million.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.29. Analysts anticipate that Collegium Pharmaceutical Inc. will post ($3.88) EPS for the current fiscal year.

In other news, Director John A. Fallon purchased 2,375 shares of the business’s stock in a transaction on Friday, August 12th. The stock was purchased at an average cost of $10.59 per share, with a total value of $25,151.25. Following the acquisition, the director now directly owns 2,375 shares in the company, valued at $25,151.25. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.